{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:43:14Z","timestamp":1771267394866,"version":"3.50.1"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Emicizumab mimics the hemostatic activity of activated factor VIII (FVIIIa) within the tenase complex. Despite functional similarities between FVIIIa and emicizumab, conventional laboratory methods designed for monitoring of FVIII activity are inappropriate for the measurement of emicizumab. At present, a modified one stage (FVIII) assay (mOSA) is mainly used for emicizumab monitoring. Two-stage chromogenic FVIII assays based on human factors can be used, although limited performance due to lack of corresponding optimization might be observed. Furthermore, the presence of FVIII or anticoagulants in the patient sample may falsify assay results. To address these issues, we optimized and evaluated a two-stage chromogenic assay (emi-tenase) for measurement of emicizumab in plasma samples. Heat inactivation of samples was established to abolish the influence of endogenous or substituted FVIII. The lower limit of quantification (LLoQ) was found to be 2 \u03bcg\/ml in a manual assay format and 9.5 \u03bcg\/ml on an automated coagulation analyzer. Intra- and inter-assay coefficients of variation (CV) did not exceed 20%. Analysis of 17 patient plasma samples with severe haemophilia A under emicizumab treatment showed good correlation of results between the emi-tenase assay and the mOSA (Cohens Kappa coefficient = 0.9). Taken together, the emi-tenase assay allows specific measurement of emicizumab plasma levels over a broad concentration range (10 \u03bcg\/ml to 100 \u03bcg\/ml). The assay can be applied on an automated coagulation analyzer, demonstrating its applicability within a routine laboratory setting.<\/jats:p>","DOI":"10.1371\/journal.pone.0271330","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T17:32:12Z","timestamp":1657819932000},"page":"e0271330","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1454-5090","authenticated-orcid":true,"given":"Nasim Shahidi","family":"Hamedani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"P\u00f6tzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"issue":"10040","key":"pone.0271330.ref001","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"F Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"pone.0271330.ref002","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"A Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"S1","key":"pone.0271330.ref003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ijlh.12659","article-title":"Factor VIII inhibitors: Advances in basic and translational science","volume":"39","author":"JD Lai","year":"2017","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"pone.0271330.ref004","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.","volume":"109","author":"J Astermark","year":"2006","journal-title":"Blood"},{"issue":"18","key":"pone.0271330.ref005","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"C Leissinger","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0271330.ref006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hae.13050","article-title":"A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors","volume":"23","author":"Y Shinkoda","year":"2017","journal-title":"Haemophilia"},{"issue":"5","key":"pone.0271330.ref007","first-page":"457","article-title":"Non-factor replacement therapy for haemophilia: a current update","volume":"16","author":"M Franchini","year":"2018","journal-title":"Blood Transfus"},{"issue":"6","key":"pone.0271330.ref008","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1055\/s-0037-1612626","article-title":"Inhibitors in Hemophilia: Treatment Challenges and Novel Options.","volume":"44","author":"AA Barg","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"pone.0271330.ref009","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40265-018-0861-2","article-title":"Emicizumab-kxwh: First Global Approval.","volume":"78","author":"LJ Scott","year":"2018","journal-title":"Drugs"},{"issue":"9","key":"pone.0271330.ref010","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0271330.ref011","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0271330.ref012","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"T Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"pone.0271330.ref013","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"A Muto","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"23","key":"pone.0271330.ref014","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"PJ Lenting","year":"2017","journal-title":"Blood"},{"issue":"1","key":"pone.0271330.ref015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12185-018-2545-9","article-title":"Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity","volume":"111","author":"T Kitazawa","year":"2020","journal-title":"Int J Hematol"},{"issue":"6","key":"pone.0271330.ref016","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"SW Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"24","key":"pone.0271330.ref017","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"G Young","year":"2019","journal-title":"Blood"},{"issue":"3","key":"pone.0271330.ref018","first-page":"229","article-title":"Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL","volume":"17","author":"A Tripodi","year":"2019","journal-title":"Blood Transfus"},{"issue":"21","key":"pone.0271330.ref019","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"M Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0271330.ref020","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1111\/hae.14264","article-title":"Approximation of emicizumab plasma levels in emergency situations. A practical approach.","volume":"27","author":"I Pekrul","year":"2021","journal-title":"Haemophilia"},{"key":"pone.0271330.ref021","author":"S. Shinohara","year":"2019"},{"issue":"7","key":"pone.0271330.ref022","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"JI Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"9","key":"pone.0271330.ref023","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"J M\u00fcller","year":"2019","journal-title":"Thromb Haemost"},{"issue":"10","key":"pone.0271330.ref024","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/jth.13795","article-title":"Limit of detection and threshold for positivity of the centers for disease control and prevention assay for factor VIII inhibitors","volume":"15","author":"CH Miller","year":"2017","journal-title":"J Thromb Haemost"},{"key":"pone.0271330.ref025","doi-asserted-by":"crossref","DOI":"10.1002\/9781118543467.ch2","article-title":"Hemostasis test validation, performance, and reference intervals: international recommendations and guidelines","author":"RA Marlar","year":"2013","journal-title":"In Quality in laboratory hemostasis and thrombosis"},{"issue":"Suppl 3","key":"pone.0271330.ref026","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2516.2006.01278.x","article-title":"Achieving and maintaining quality in the laboratory","volume":"12","author":"MS Hertzberg","year":"2006","journal-title":"Haemophilia"},{"issue":"8476","key":"pone.0271330.ref027","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"JM Bland","year":"1986","journal-title":"Lancet"},{"issue":"14","key":"pone.0271330.ref028","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1073\/pnas.94.14.7176","article-title":"The primary fibrin polymerization pocket: Three-dimensional structure of a 30-kDa C-terminal \u03b3 chain fragment complexed with the peptide Gly-Pro-Arg-Pro","volume":"94","author":"KP Pratt","year":"1997","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"7","key":"pone.0271330.ref029","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"T Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"issue":"4","key":"pone.0271330.ref030","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/hae.12639","article-title":"Current laboratory practices in the diagnosis and management of haemophilia: a global assessment","volume":"21","author":"S Kitchen","year":"2015","journal-title":"Haemophilia"},{"issue":"4","key":"pone.0271330.ref031","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/jth.13253","article-title":"A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays","volume":"14","author":"S Kitchen","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"pone.0271330.ref032","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.13339","article-title":"Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B","volume":"104","author":"RA Marlar","year":"2020","journal-title":"Eur J Haematol"},{"issue":"3","key":"pone.0271330.ref033","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.transci.2018.05.020","article-title":"Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients","volume":"57","author":"J Amiral","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"pone.0271330.ref034","article-title":"Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring","author":"AA Barg","year":"2021","journal-title":"Haemophilia"},{"issue":"6","key":"pone.0271330.ref035","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1055\/s-0040-1710315","article-title":"Emicizumab improves ex vivo clotting function in patients with mild\/moderate hemophilia A","volume":"120","author":"Y Nakajima","year":"2020","journal-title":"Thromb Haemost"},{"issue":"3","key":"pone.0271330.ref036","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"P Knoebl","year":"2021","journal-title":"Blood"},{"issue":"2","key":"pone.0271330.ref037","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1515\/cclm-2020-0696","article-title":"Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma","volume":"59","author":"A Tripodi","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"pone.0271330.ref038","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/hae.13901","article-title":"Evaluation of pre-analytic heat treatment protocol used in the CDC Nijmegen-Bethesda assay for heat inactivation of extended half-life haemophilia treatment products","volume":"26","author":"AB Payne","year":"2020","journal-title":"Haemophilia"},{"key":"pone.0271330.ref039","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2019.06.005","article-title":"When innovation goes fast. The case of hemophilia","volume":"45","author":"D Pilunni","year":"2019","journal-title":"Curr Opin Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0271330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T15:41:20Z","timestamp":1700840480000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0271330"}},"subtitle":[],"editor":[{"given":"Arijit","family":"Biswas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0271330","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}